Metaplastic Breast Carcinoma: Analysis of 44 Cases

Abstract

In the present research, a full series of 44 cases investigating metaplastic breast carcinoma (MBC) have been presented to clarify uncertainty in variables for diagnosis, categorization, and treatment strategies. Forty-four MBC female patients have been treated between Jan 2009 and Dec 2019 were retrospectively investigated and presented in this research. Demographic characteristics of the patients, types of surgery, tumor sizes, axillary involvement, tumor stages, and planned adjuvant treatments were considered and evaluated using the database of the hospital. Tumor diameter was less than 20 mm in 8 cases (18.8%), in between 20 and 50 mm in 23 cases (52.2%), and greater than 50 mm in 13 cases (29.5%). Both estrogen and progesterone receptors were found negative in 38 cases, and positive in 6 cases. The mean Ki-67 expression was determined as 51.36 ± 31.20 (range, 2 to 90) in 44 cases (100%). The mean follow-up period was 59.8 ± 39.4 (range, 10 to 120) months. All cases were alive during the follow-up. In the present research, an investigation with one of the largest single-institution data with the patients with MBC is presented. It is also critical that MBC has been associated with a poor prognosis, despite the low nodal involvement. Most patients in the series had negative axillary lymph node involvement, large tumor diameter, and hormone receptor negativity. Therefore, the present research is valuable in the literature and beneficial for researchers and readers.